Drug-induced liver injury.
暂无分享,去创建一个
[1] P. Nicotera,et al. Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and Necrosis , 1997, The Journal of experimental medicine.
[2] M Pirmohamed,et al. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. , 1998, Chemical research in toxicology.
[3] Munir Pirmohamed,et al. The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.
[4] Z. Ackerman,et al. Hypersensitivity reactions to drugs in acquired immunodeficiency syndrome. , 1987, Postgraduate medical journal.
[5] J. Lefkowitch,et al. Mixed HepatocellularCholestatic Liver Injury after Pioglitazone Therapy , 2002, Annals of Internal Medicine.
[6] G. Lehman,et al. Chemotherapy-induced sclerosing cholangitis. , 2006, Clinical radiology.
[7] K. Ishak,et al. Diclofenac‐associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions , 1995, Hepatology.
[8] R Williams,et al. Early indicators of prognosis in fulminant hepatic failure. , 1989, Gastroenterology.
[9] W. Pichler,et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. , 1997, The Journal of clinical investigation.
[10] D. Stewart,et al. Hepatic Adverse Reactions Associated with Nefazodone , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[11] H. Motanis,et al. Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects , 2006, Acta Pharmacologica Sinica.
[12] M. Shevell. Pemoline associated hepatic failure: a critical analysis of the literature. , 1997, Pediatric neurology.
[13] Yuan-Tsong Chen,et al. A marker for Stevens–Johnson syndrome , 2004 .
[14] T. Noll,et al. Halothane Hepatotoxicity: Relation Between Metabolic Activation, Hypoxia, Covalent Binding, Lipid Peroxidation and Liver Cell Damage , 2007, Hepatology.
[15] G. Alexander,et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity , 2004, Hepatology.
[16] S. Dower,et al. Regulation of Toll-Like Receptors in Human Monocytes and Dendritic Cells1 , 2001, The Journal of Immunology.
[17] G. Hamilton,et al. Isolation and culture of primary human hepatocytes. , 2005, Methods in molecular biology.
[18] Y. Liaw,et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: A controlled cohort study , 1997, Hepatology.
[19] Marina Núñez,et al. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. , 2006, Journal of hepatology.
[20] P. McCormick,et al. Nimesulide associated fulminant hepatic failure , 2008, Pharmacoepidemiology and drug safety.
[21] S. Strom,et al. Influence of Matrigel-overlay on constitutive and inducible expression of nine genes encoding drug-metabolizing enzymes in primary human hepatocytes , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[22] A. Fernández-Villar,et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[23] J. Rabkin,et al. Fatal Fulminant Hepatitis Associated with Bromfenac Use , 1999, The Annals of pharmacotherapy.
[24] Ali Olyaei,et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. , 2003, Archives of surgery.
[25] T. Ahrens,et al. Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4 , 2002, The Journal of experimental medicine.
[26] H. Masumoto,et al. Covalent Binding and Tissue Distribution/Retention Assessment of Drugs Associated with Idiosyncratic Drug Toxicity , 2008, Drug Metabolism And Disposition.
[27] J. Gurwitz,et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. , 2003, Archives of internal medicine.
[28] D. Larrey. Drug-induced liver diseases. , 2000, Journal of hepatology.
[29] Hojoong Kim,et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. , 2005, Chest.
[30] A. J. Gandolfi,et al. Identification of the dihydrolipoamide acetyltransferase subunit of the human pyruvate dehydrogenase complex as an autoantigen in halothane hepatitis. Molecular mimicry of trifluoroacetyl-lysine by lipoic acid. , 1994, European journal of biochemistry.
[31] S. Pol,et al. Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy , 2002, Journal of viral hepatitis.
[32] P. Hillon,et al. Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.
[33] M. Pirmohamed,et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. , 2003, The Journal of allergy and clinical immunology.
[34] R. DeMatteo,et al. Liver Dendritic Cells Are Less Immunogenic Than Spleen Dendritic Cells because of Differences in Subtype Composition1 , 2004, The Journal of Immunology.
[35] B. Martin,et al. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[36] H. Echizen,et al. Risk factors for antituberculous chemotherapy‐induced hepatotoxicity in Japanese pediatric patients , 2002, Clinical pharmacology and therapeutics.
[37] L. Pohl,et al. Autoantibodies Associated with Volatile Anesthetic Hepatitis Found in the Sera of a Large Cohort of Pediatric Anesthesiologists , 2002, Anesthesia and analgesia.
[38] N. Pumford,et al. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species , 1999, Hepatology.
[39] R. Talaat,et al. Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. , 2001, Biochemical pharmacology.
[40] J. Greenwood,et al. Letter: Exploration of the common bileduct. , 1974, Lancet.
[41] James E. Evans,et al. Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.
[42] F. T. P. Group,et al. Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens , 2007, Drug safety.
[43] G. Aithal,et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. , 2007, Gastroenterology.
[44] G. Obermoser,et al. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis , 2003, Lupus.
[45] E. Schiff,et al. Liver enzymes elevation after HAART in HIV‐HCV co‐infection , 2005, Journal of viral hepatitis.
[46] Susan K. Lazerow,et al. Drug-induced liver disease 2004 , 2005, Current opinion in gastroenterology.
[47] G. Danan,et al. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.
[48] P. Watkins,et al. Hepatic dysfunction associated with troglitazone. , 1998, The New England journal of medicine.
[49] W. Pichler. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept , 2002, Current opinion in allergy and clinical immunology.
[50] M. Loeb,et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[51] H. V. van Buuren,et al. Rosuvastatin-associated hepatitis with autoimmune features. , 2005, European journal of gastroenterology & hepatology.
[52] T. Rochat,et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis , 2005, European Respiratory Journal.
[53] R. Cheung,et al. Incidence of statin hepatotoxicity in patients with hepatitis C. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[54] H. Satoh,et al. Neoantigens associated with halothane hepatitis. , 1989, Drug metabolism reviews.
[55] R. Dart,et al. The clinical spectrum of Jin Bu Huan toxicity. , 1996, Archives of internal medicine.
[56] K. Elgjo,et al. Sulfonamide-induced chronic liver disease. , 1974, Scandinavian journal of gastroenterology.
[57] R. Talbert. Safety issues with statin therapy. , 2006, Journal of the American Pharmacists Association : JAPhA.
[58] H. Jaeschke,et al. Pathophysiological role of the acute inflammatory response during acetaminophen hepatotoxicity. , 2006, Toxicology and applied pharmacology.
[59] N. Chalasani,et al. An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.
[60] J. Castellsagué,et al. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. , 2006, Clinical therapeutics.
[61] Esther F. Schmid,et al. Drug withdrawals and the lessons within. , 2006, Current opinion in drug discovery & development.
[62] Meehyung Cho,et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.
[63] S. Mallal,et al. HLA and drug-induced toxicity. , 2009, Current opinion in molecular therapeutics.
[64] G. Cadiot,et al. Atteinte hépatique aiguë cholestatique induite par le glimépiride , 2004 .
[65] Richard D Moore,et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir , 2004, AIDS.
[66] S. Paisley,et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials , 2009, Journal of internal medicine.
[67] E. Farley-Hills,et al. Fatal liver failure associated with pioglitazone , 2004, BMJ : British Medical Journal.
[68] C. Sato,et al. Autoimmune hepatitis triggered by administration of an herbal medicine. , 1997, The American journal of gastroenterology.
[69] L. Seeff,et al. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. , 1986, Annals of internal medicine.
[70] D. Parra,et al. Effectiveness and Hepatotoxicity of Statins in Men Seropositive for Hepatitis C Virus , 2007, Pharmacotherapy.
[71] L. Powell,et al. Sulindac hepatotoxicity: effects of acute and chronic exposure. , 1985, Australian and New Zealand journal of medicine.
[72] P. Beaune,et al. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. , 1994, Molecular pharmacology.
[73] L. Forman,et al. Hepatic Failure in a Patient Taking Rosiglitazone , 2000, Annals of Internal Medicine.
[74] A. Farhood,et al. The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[75] G. H. Thompson,et al. Comparative Tolerability Profiles of the Inhaled Anaesthetics , 1997, Drug safety.
[76] Joe Kesterson,et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.
[77] P. Beaune,et al. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. , 1996, Molecular pharmacology.
[78] Lynde,et al. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature , 1998, Clinical and experimental dermatology.
[79] B. Stricker,et al. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. , 1986, Journal of hepatology.
[80] K. Tolman. The liver and lovastatin. , 2002, The American journal of cardiology.
[81] M Pirmohamed,et al. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. , 2000, Toxicology.
[82] P. Watkins,et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[83] U. Walker,et al. Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. , 2008, The American journal of pathology.
[84] J. Lewis,et al. Review article: the use of potentially hepatotoxic drugs in patients with liver disease , 2008, Alimentary pharmacology & therapeutics.
[85] P. Venkatesan,et al. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. , 1986, The American review of respiratory disease.
[86] U. Christen,et al. Molecular mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins and immunochemical evidence for its impairment in halothane hepatitis. , 1992, European journal of biochemistry.
[87] F. Dreifuss,et al. Valproic acid hepatic fatalities. III. U.S. experience since 1986 , 1996, Neurology.
[88] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[89] E. Björnsson,et al. Drug‐induced liver injury in a Swedish University hospital out‐patient hepatology clinic , 2006, Alimentary pharmacology & therapeutics.
[90] J. Brady,et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. , 2001, Chemical research in toxicology.
[91] S. Luque,et al. Risk of side effects associated with the use of nevirapine in treatment‐naïve patients, with respect to gender and CD4 cell count , 2008, HIV medicine.
[92] L. Pohl,et al. Pathogenic role of natural killer T and natural killer cells in acetaminophen‐induced liver injury in mice is dependent on the presence of dimethyl sulfoxide , 2008, Hepatology.
[93] R. Temple,et al. Safety of newly approved drugs: implications for prescribing. , 2002, JAMA.
[94] M. Hartleb,et al. Drug-induced liver damage -- a three-year study of patients from one gastroenterological department. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[95] J. Luyendyk,et al. Inflammation and Drug Idiosyncrasy—Is There a Connection? , 2003, Journal of Pharmacology and Experimental Therapeutics.
[96] K. Reddy,et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. , 2004, Journal of hepatology.
[97] J. Neuberger. Halothane and Hepatitis , 1990 .
[98] R. Kedl,et al. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells , 2008, Hepatology.
[99] Michael J Liguori,et al. Modest Inflammation Enhances Diclofenac Hepatotoxicity in Rats: Role of Neutrophils and Bacterial Translocation , 2006, Journal of Pharmacology and Experimental Therapeutics.
[100] William M. Lee,et al. Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.
[101] E. Kharasch. Adverse Drug Reactions With Halogenated Anesthetics , 2008, Clinical pharmacology and therapeutics.
[102] L. Pohl,et al. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. , 2003, Biochemical and biophysical research communications.
[103] H. Satoh,et al. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. , 1988, The Journal of pharmacology and experimental therapeutics.
[104] K. Tolman,et al. Hepatotoxicity of non-narcotic analgesics. , 1998, The American journal of medicine.
[105] B. K. Park,et al. Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac. , 2004, Journal of medicinal chemistry.
[106] D. Pessayre,et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. , 1998, Gastroenterology.
[107] H. Satoh,et al. The immunologic and metabolic basis of drug hypersensitivities. , 1988, Annual review of pharmacology and toxicology.
[108] M. Ziol,et al. [Acute cholestatic hepatitis induced by glimepiride]. , 2000, Gastroenterologie clinique et biologique.
[109] E. Keeffe,et al. Prolonged cholestasis due to trimethoprim sulfamethoxazole. , 1992, Gastroenterology.
[110] William M. Lee,et al. Acute Liver Failure Due To Amoxicillin and Amoxicillin/Clavulanate , 2005, Digestive Diseases and Sciences.
[111] Polly Matzinger,et al. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.
[112] K. Lindor,et al. Drug-induced cholestasis. , 2003, Clinics in liver disease.
[113] R. Kessler,et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress , 2002, Psychological Medicine.
[114] J. Angel,et al. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[115] M. Vecchi,et al. Inappropriate pemoline therapy leading to acute liver failure and liver transplantation. , 2002, Digestive and Liver Disease.
[116] H. Jick,et al. Erythromycin‐Associated Cholestatic Hepatitis , 1993, The Medical journal of Australia.
[117] B. Rumack,et al. Acetaminophen poisoning and toxicity. , 1975, Pediatrics.
[118] J. P. Garvin,et al. Halothane and Children: The First Quarter Century , 1984, Anesthesia and analgesia.
[119] Van Dyke Ra,et al. Halothane Hepatitis: A Critical Review , 1972, Anesthesia and analgesia.
[120] G. Tarantino,et al. A prospective study of acute drug‐induced liver injury in patients suffering from non‐alcoholic fatty liver disease , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[121] C. Janeway,et al. Innate immune recognition. , 2002, Annual review of immunology.
[122] B. Stricker,et al. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. , 1996, Archives of internal medicine.
[123] P. Braun. Hepatotoxicity of erythromycin. , 1969, The Journal of infectious diseases.
[124] H. Bonkovsky,et al. Autoimmune hepatitis triggered by statins. , 2006, Journal of clinical gastroenterology.
[125] E. Björnsson,et al. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. , 2006, Journal of hepatology.
[126] Chandan Saha,et al. Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals , 2008, Hepatology.
[127] W. Bernal. Changing Patterns of Causation and the Use of Transplantation in the United Kingdom , 2003, Seminars in liver disease.
[128] F. Larsen,et al. MELD score as a predictor of liver failure and death in patients with acetaminophen‐induced liver injury , 2007, Hepatology.
[129] Michael P Holt,et al. Effect of polyI:C cotreatment on halothane‐induced liver injury in mice , 2009, Hepatology.
[130] J. Hoofnagle,et al. Drug‐induced liver injury network (DILIN) , 2004, Hepatology.
[131] L. Kwak,et al. Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by β-Defensin 2 , 2002, Science.
[132] A. Daly,et al. Flucloxacillin-induced liver injury. , 2008, Toxicology.
[133] R. Fontana,et al. Drug-Induced Liver Injury Network (DILIN) Prospective Study , 2009, Drug safety.
[134] P. Reiss,et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.
[135] M. Ferrante,et al. Acute hepatitis induced by greater celandine (Chelidonium majus). , 2008, Acta gastro-enterologica Belgica.
[136] F. Ayd. Chlorpromazine: ten years' experience. , 1963, JAMA.
[137] T. Miller,et al. Role of neutrophils in hepatotoxicity induced by oral acetaminophen administration in rats. , 1998, The Journal of surgical research.
[138] L. Laine,et al. How Common Is Diclofenac-Associated Liver Injury? Analysis of 17,289 Arthritis Patients in a Long-Term Prospective Clinical Trial , 2009, The American Journal of Gastroenterology.
[139] Yi-Shin Huang. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury , 2007, Expert opinion on drug metabolism & toxicology.
[140] J. Lindenbaum,et al. HEPATIC NECROSIS ASSOCIATED WITH HALOTHANE ANESTHESIA , 1963, The New England journal of medicine.
[141] D. Pessayre,et al. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. , 1996, Gastroenterology.
[142] S. Erlinger. Drug-induced cholestasis. , 1997, Journal of hepatology.
[143] P. Ganey,et al. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. , 2001, Toxicology.
[144] C. Bénichou. Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.
[145] K. Anderson,et al. Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase* , 2001, The Journal of Biological Chemistry.
[146] R. Schulick,et al. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. , 1985, Molecular pharmacology.
[147] T. Baillie,et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. , 2001, Chemical research in toxicology.
[148] G. Aithal,et al. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. , 2007, Clinics in liver disease.
[149] James H. Lewis,et al. Drug-induced liver disease. , 2003, Current opinion in gastroenterology.
[150] H. Zimmerman,et al. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. , 1995, Critical reviews in toxicology.
[151] K. Brouwer,et al. P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepatocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide , 2004, Pharmaceutical Research.
[152] E. Kharasch,et al. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. , 1997, The Journal of pharmacology and experimental therapeutics.
[153] L. Pohl,et al. Protection against acetaminophen‐induced liver injury and lethality by interleukin 10: Role of inducible nitric oxide synthase , 2002, Hepatology.
[154] R. Andrade,et al. Phenotypic characterization of idiosyncratic drug‐induced liver injury: The influence of age and sex , 2009, Hepatology.
[155] J. Waring,et al. Microarray Analysis of Lipopolysaccharide Potentiation of Trovafloxacin-Induced Liver Injury in Rats Suggests a Role for Proinflammatory Chemokines and Neutrophils , 2006, Journal of Pharmacology and Experimental Therapeutics.
[156] J. Yarze,et al. Pioglitazone-associated fulminant hepatic failure. , 2002 .
[157] Richard D Moore,et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus , 2005, AIDS.
[158] R. N. Macsween,et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association , 2000, Gut.
[159] M. Wang,et al. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. , 1998, Journal of immunology.
[160] N. Kaplowitz,et al. Clinical Perspectives on Xenobiotic‐Induced Hepatotoxicity , 2004, Drug metabolism reviews.
[161] N. Kaplowitz,et al. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. , 2004, Gastroenterology.
[162] W. Trager,et al. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. , 1999, Biochemistry.
[163] B. Stricker,et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. , 2001, British journal of clinical pharmacology.
[164] A. J. Gandolfi,et al. Bioactivation and covalent binding of halothane in vitro: studies with [3H]- and [14C]halothane. , 1980, The Journal of pharmacology and experimental therapeutics.
[165] S. Nelson,et al. The complex interaction between ethanol and acetaminophen , 1996, Clinical pharmacology and therapeutics.
[166] R. Chaisson,et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.
[167] C. Funk,et al. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. , 2001, Molecular pharmacology.
[168] R. Green,et al. Mechanism of indinavir-induced hyperbilirubinemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[169] D. Schuppan,et al. Hepatitis induced by Kava (Piper methysticum rhizoma). , 2003, Journal of hepatology.
[170] M. Luster,et al. Role of inflammation in chemical-induced hepatotoxicity. , 2001, Toxicology letters.
[171] D. Larrey,et al. Hepatitis after Germander (Teucrium chamaedrys) Administration: Another Instance of Herbal Medicine Hepatotoxicity , 1992, Annals of Internal Medicine.
[172] S. Tsiodras,et al. Cholestatic liver injury after glimepiride therapy. , 2005, Journal of hepatology.
[173] K. Ishak,et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. , 1993, Gastroenterology.
[174] R. Andrade,et al. Comparison of two clinical scales for causality assessment in hepatotoxicity , 2001, Hepatology.
[175] L. Pohl,et al. Tolerogenic role of Kupffer cells in immune-mediated adverse drug reactions. , 2005, Toxicology.
[176] M. Pirmohamed,et al. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. , 2001, Chemical research in toxicology.
[177] F. Villamil,et al. Acute Hepatitis Associated with the Chinese Herbal Product Jin Bu Huan , 1994, Annals of Internal Medicine.
[178] E. Gale. Lessons from the glitazones: a story of drug development , 2001, The Lancet.
[179] D. Gottlieb,et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. , 1996, American journal of respiratory and critical care medicine.
[180] J. Xu,et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[181] P. Watkins,et al. Severe acetaminophen toxicity in a patient receiving isoniazid. , 1990, Annals of internal medicine.
[182] H. Ljunggren,et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance , 2000, Nature Medicine.
[183] N. Sinelli,et al. Chronic hepatitis induced by Jin Bu Huan. , 1998, Journal of hepatology.
[184] E. Eger. Characteristics of anesthetic agents used for induction and maintenance of general anesthesia. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[185] N. Mukaida,et al. Opposite roles of neutrophils and macrophages in the pathogenesis of acetaminophen‐induced acute liver injury , 2006, European journal of immunology.
[186] Michael P Holt,et al. Mechanisms of drug-induced liver injury , 2006, The AAPS Journal.
[187] H. Zimmerman,et al. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure , 1995, Hepatology.
[188] E. Vittinghoff,et al. Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial , 2002, Annals of Internal Medicine.
[189] I. Onorato,et al. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[190] R. Andrade,et al. HLA class II genotype influences the type of liver injury in drug‐induced idiosyncratic liver disease , 2004, Hepatology.
[191] D. Larrey,et al. Hépatites observées au cours d'un traitement par un médicament ou une tisane contenant de la Germandrée petit-chêne : bilan des 26 cas rapportés aux centres régionaux de pharmacovigilance , 1992 .
[192] V. Hogan. Pemoline (Cylert): market withdrawal. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[193] J. Montaner,et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts * , 2008, HIV medicine.
[194] M. Pirmohamed,et al. Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T Cells from Allergic Individuals1 , 2000, The Journal of Immunology.
[195] J. Luyendyk,et al. Neutrophil Interaction with the Hemostatic System Contributes to Liver Injury in Rats Cotreated with Lipopolysaccharide and Ranitidine , 2007, Journal of Pharmacology and Experimental Therapeutics.
[196] H. Poulsen,et al. Acute versus chronic alcohol consumption in acetaminophen‐induced hepatotoxicity , 2002, Hepatology.
[197] Dominic P. Williams,et al. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science , 2008, Expert opinion on drug metabolism & toxicology.
[198] J. G. Kenna,et al. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. , 1996, Molecular pharmacology.
[199] F. Lombardo,et al. BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4 , 2005, Drug Metabolism and Disposition.
[200] O. Eade,et al. CONTROLLED PROSPECTIVE STUDY OF THE EFFECT ON LIVER FUNCTION OF MULTIPLE EXPOSURES TO HALOTHANE , 1975, The Lancet.
[201] M. Pirmohamed,et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. , 2003, Molecular pharmacology.
[202] J. Neuberger,et al. Halothane hepatitis: a model of immune mediated drug hepatotoxicity. , 1987, Clinical science.
[203] R. Suresh,et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. , 2002, The American journal of cardiology.
[204] Defeng Wu,et al. Oxidative Stress and Alcoholic Liver Disease , 2009, Seminars in liver disease.
[205] R. Wilson,et al. Role of proinflammatory cytokines in acetaminophen hepatotoxicity. , 1995, Toxicology and applied pharmacology.
[206] D. Mansuy,et al. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. , 1999, Chemical research in toxicology.
[207] R. Fontana,et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.
[208] E. Björnsson,et al. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug‐induced liver injury , 2007, Alimentary pharmacology & therapeutics.
[209] M. Cousins,et al. Guinea-pig model of halothane-associated hepatotoxicity in the absence of enzyme induction and hypoxia. , 1985, The Journal of pharmacology and experimental therapeutics.
[210] J. Marshall,et al. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. , 1996, The American journal of gastroenterology.
[211] K. Miller,et al. Lactic Acidosis and Hepatic Steatosis Associated with Use of Stavudine: Report of Four Cases , 2000, Annals of Internal Medicine.
[212] D. Thiel,et al. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity , 2000, American Journal of Gastroenterology.
[213] Anastasios Koulaouzidis,et al. Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. , 2007, Annals of hepatology.
[214] D. Dieterich,et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[215] H. Zimmerman,et al. Drug- and chemical-induced cholestasis. , 1999, Clinics in liver disease.
[216] T. Rushmore,et al. Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility. , 2001, Chemical research in toxicology.
[217] M. Mittal,et al. Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report , 2000, Annals of Internal Medicine.
[218] S. Lawson-Ayayi,et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[219] Sean S. Park,et al. Severe Hepatotoxicity Associated with the Dietary Supplement LipoKinetix , 2002, Annals of Internal Medicine.
[220] S. Sherman,et al. Chemotherapy-Induced Sclerosing Cholangitis: Long-term Response to Endoscopic Therapy , 2006, Journal of clinical gastroenterology.
[221] L. Lasagna,et al. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective , 1995, Clinical pharmacology and therapeutics.
[222] M. Sulkowski,et al. Viral hepatitis and HIV coinfection. , 2008, Journal of hepatology.
[223] R. Idilman,et al. Antituberculous therapy–induced fulminant hepatic failure: Successful treatment with liver transplantation and nonstandard antituberculous therapy , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[224] R. Andrade,et al. Determinants of the clinical expression of amoxicillin‐clavulanate hepatotoxicity: A prospective series from Spain , 2006, Hepatology.
[225] T. Self,et al. Rifampin Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection , 2009, The American journal of the medical sciences.
[226] J. Reichen,et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. , 2007, Journal of hepatology.
[227] E. Randinitis,et al. Meta‐Analysis of Steady‐State Pharmacokinetics of Troglitazone and Its Metabolites , 1997, Journal of clinical pharmacology.
[228] T. Sterling,et al. American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy , 2006 .
[229] G. Tarantino,et al. Drug-induced liver injury: is it somehow foreseeable? , 2009, World journal of gastroenterology.
[230] D. Pessayre,et al. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. , 1995, Pharmacology & therapeutics.
[231] W. Pichler. Direct T-cell stimulations by drugs--bypassing the innate immune system. , 2005, Toxicology.
[232] Andrew Phillips,et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy , 2001, AIDS.
[233] M. A. Steele,et al. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. , 1991, Chest.
[234] T. Marcy,et al. Second-Generation Thiazolidinediones and Hepatotoxicity , 2004, The Annals of pharmacotherapy.
[235] B. Neuschwander‐Tetri,et al. Nafcillin-associated hepatotoxicity , 2005, Digestive Diseases and Sciences.
[236] J. McNeil,et al. Risk factors for development of flucloxacillin associated jaundice. , 1993, BMJ.
[237] D. Parratt,et al. IgM and IgG antibody levels to ampicillin in patients with infectious mononucleosis. , 1976, Clinical and experimental immunology.
[238] M. Lederman,et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. , 2005, The Journal of infectious diseases.
[239] A. J. Gandolfi,et al. Covalent binding of oxidative biotransformation intermediates is associated with halothane hepatotoxicity in guinea pigs. , 1990, Anesthesiology.
[240] D. Wegmann,et al. Role of neutrophils in a mouse model of halothane‐induced liver injury , 2006, Hepatology.
[241] L. Pohl,et al. Tolerogenic role of Kupffer cells in allergic reactions. , 2003, Chemical research in toxicology.
[242] M. Britschgi,et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole‐specific and sulfamethoxazole‐metabolite‐specific human CD4+ T‐cells , 2001, British journal of pharmacology.
[243] E. Eger,et al. Biotransformation of Halothane, Enflurane, Isoflurane, and Desflurane to Trifluoroacetylated Liver Proteins: Association Between Protein Acylation and Hepatic Injury , 1997, Anesthesia and analgesia.
[244] Antibody-independent activation of the complement system by mitochondria is mediated by cardiolipin. , 1988, The Biochemical journal.
[245] William M. Lee,et al. Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.
[246] D. Safer,et al. Pemoline hepatotoxicity and postmarketing surveillance. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[247] S. Itoh,et al. Liver injuries induced by herbal medicine, Syo-saiko-to (xiao-chai-hu-tang) , 1995, Digestive Diseases and Sciences.
[248] N. Kaplowitz,et al. Drug-Induced Liver Disorders , 2001, Drug safety.
[249] D. Larrey. Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver , 2002, Seminars in liver disease.
[250] V. Soriano,et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. , 2007, The Journal of infectious diseases.
[251] C. Moore,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.
[252] J. Brady,et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. , 2002, Chemical research in toxicology.
[253] M. Davis,et al. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. , 1999, Chemical research in toxicology.
[254] E. Björnsson,et al. Outcome and prognostic markers in severe drug‐induced liver disease , 2005, Hepatology.
[255] M. Rawlins,et al. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. , 2000, Journal of hepatology.
[256] F. Ballet,et al. Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.
[257] M. Luster,et al. Histopathology of Acetaminophen-Induced Liver Changes: Role of Interleukin 1α and Tumor Necrosis Factor α , 1996 .
[258] Richard J. Thompson,et al. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. , 2002, Gastroenterology.
[259] M. Sharifzadeh,et al. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment , 2005 .
[260] Sarah A. Slavoff,et al. Isolation and characterisation of selected germander diterpenoids from authenticated Teucrium chamaedrys and T. canadense by HPLC, HPLC-mS and NMR. , 2006, Phytochemical analysis : PCA.
[261] Stephen L. Leib,et al. Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. , 2009, Journal of hepatology.
[262] R. Ridzon,et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. , 1997, American journal of respiratory and critical care medicine.
[263] Michael Rehli,et al. Novel Signal Transduction Pathway Utilized by Extracellular HSP70 , 2002, The Journal of Biological Chemistry.
[264] J. Senior,et al. Troglitazone-induced liver failure: a case study. , 2003, The American journal of medicine.
[265] B. Stricker,et al. Hepatic injury associated with the use of nitrofurans: A clinicopathological study of 52 reported cases , 1988, Hepatology.
[266] J. Uetrecht,et al. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.
[267] R. Sweet,et al. Halothane Anesthesia as a Possible Cause of Massive Hepatic Necrosis , 1963, Anesthesiology.
[268] A. Aceti,et al. Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV: The Role of Hepatitis B and C Virus Infection , 2002, Journal of acquired immune deficiency syndromes.
[269] R. Cardell,et al. Hepatic Necrosis Caused by Halothane and Hypoxia in Phenobarbital‐treated Rats , 1979, Anesthesiology.
[270] E. Bjornsson,et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events , 2010, Hepatology.
[271] M. Kaito,et al. Spirulina-associated hepatotoxicity , 2002, American Journal of Gastroenterology.
[272] K. Ishak,et al. Cholestatic and hepatocellular injury associated with erythromycin esters , 1979, Digestive Diseases and Sciences.
[273] P. Allavena,et al. Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic Cells1 , 2000, The Journal of Immunology.
[274] J. Murdoch,et al. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. , 1967, Lancet.
[275] J. Timbrell,et al. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. , 1978, The Journal of pharmacology and experimental therapeutics.
[276] J. Stachnik,et al. Inhaled anesthetic agents. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[277] C. Leung,et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. , 2008, American journal of respiratory and critical care medicine.
[278] G. Gerken,et al. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. , 1999, Gastroenterology.
[279] K. Ishak,et al. Isoniazid-associated hepatitis in 114 patients. , 1975, Gastroenterology.
[280] F. Chang,et al. Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang. , 2006, Journal of the Chinese Medical Association : JCMA.
[281] M. Lucena,et al. Hepatotoxicity associated with the new antidepressants. , 2002, The Journal of clinical psychiatry.
[282] J. Hart,et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. , 1995, JAMA.
[283] G. Zibari,et al. Successful orthotopic liver transplantation after trimethoprim–sulfamethoxazole associated fulminant liver failure , 2003, Clinical transplantation.
[284] Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen , 1995, Hepatology.
[285] F. Chang,et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug‐induced hepatitis , 2003, Hepatology.
[286] Paul B Watkins,et al. Drug‐induced liver injury: Summary of a single topic clinical research conference , 2006, Hepatology.
[287] G. Farrell,et al. Drug-induced cholestasis , 2003, Expert opinion on drug safety.
[288] F. Stickel,et al. The efficacy and safety of comfrey , 2000, Public Health Nutrition.
[289] M. Borum. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. , 2001 .
[290] L. Pohl,et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. , 1996, Chemical research in toxicology.
[291] R. Stern,et al. Cutaneous disease and drug reactions in HIV infection. , 1993, The New England journal of medicine.
[292] W. M. Lee,et al. Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.
[293] G. Farrell,et al. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. , 2001, Journal of hepatology.
[294] K. Tashima,et al. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus. , 2006, AIDS patient care and STDs.
[295] N. Kaplowitz,et al. Neutrophil depletion protects against murine acetaminophen hepatotoxicity , 2006, Hepatology.
[296] R. Victorino,et al. Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis , 1997, Hepatology.
[297] M. Meadows. Serious liver injury. Leading reason for drug removals, restrictions. , 2001, FDA consumer.
[298] N. Mukaida,et al. A pivotal involvement of IFN‐' in the pathogenesis of acetaminophen‐induced acute liver injury , 2002 .
[299] J. Beijnen,et al. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment , 2003, AIDS.
[300] T. Hibi,et al. A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis , 2009, Journal of Gastroenterology.
[301] C. Seldenrijk,et al. Severe hepatic side effects of ezetimibe. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[302] K. Ishak,et al. Ticrynafen‐Associated Hepatic Injury: Analysis of 340 Cases , 1984, Hepatology.
[303] Peter V. Henstock,et al. Cellular imaging predictions of clinical drug-induced liver injury. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[304] M. Daly,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.
[305] Halothane hepatitis in children. , 1987, British medical journal.
[306] L. Pohl,et al. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. , 2007, Chemical research in toxicology.
[307] R. Shrestha,et al. Terbinafine‐induced hepatic failure requiring liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[308] A. J. van der Ven,et al. Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review , 2008, Journal of gastroenterology and hepatology.
[309] Daniel Hanau,et al. Heat-shock proteins as activators of the innate immune system. , 2002, Trends in immunology.
[310] P. Tien,et al. Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual. , 2008, The Journal of infectious diseases.
[311] P. Lundin,et al. Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases. , 1979, Scandinavian journal of gastroenterology.
[312] D. Vergani,et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. , 1980, The New England journal of medicine.
[313] William M. Lee,et al. Acute hepatic failure: A Western perspective , 2000, Journal of gastroenterology and hepatology.
[314] J. G. Kenna,et al. Immunoallergic drug-induced hepatitis: lessons from halothane. , 1997, Journal of hepatology.
[315] N. Kaplowitz,et al. Immune-mediated drug-induced liver disease. , 2002, Clinics in liver disease.
[316] A. Avagnina,et al. Ketoconazole-induced liver damage. , 1998, Medicina.
[317] A. J. Gandolfi,et al. Age and gender influence halothane-associated hepatotoxicity in strain 13 guinea pigs. , 1989, Anesthesiology.
[318] P. Ceppa,et al. Autoimmune hepatitis revealed by atorvastatin. , 2003, European journal of gastroenterology & hepatology.
[319] Alicja R Rudnicka,et al. Statin safety: a systematic review. , 2006, The American journal of cardiology.
[320] Luis Rodrigo,et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.
[321] M. Pirmohamed,et al. Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. , 1995, British journal of clinical pharmacology.
[322] William M. Lee,et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation , 1999 .
[323] K. Tajiri,et al. Practical guidelines for diagnosis and early management of drug-induced liver injury. , 2008, World journal of gastroenterology.
[324] C. Moore,et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.
[325] V. Soriano,et al. Risk for immune-mediated liver reactions by nevirapine revisited. , 2008, AIDS reviews.